Abstract 1362P
Background
In ALTA-3 (NCT03596866), treatment with brigatinib and alectinib showed similar efficacy in patients (pts) with ALK+ NSCLC. We report the results of an exploratory correlative pooled analysis of the association of BL ALK fusion status, as detected by ctDNA, with clinical features and outcomes in ALTA-3.
Methods
ALTA-3 was a randomized, open-label study of brigatinib 180 mg once daily (7-day lead-in at 90 mg) vs alectinib 600 mg twice daily in pts with advanced ALK+ NSCLC after progression on crizotinib. For this analysis, ALK fusion detection in plasma at BL by ctDNA sequencing was correlated with clinical features (tumor size, target lesion number, organ site involvement, smoking status) and outcomes (median progression-free survival [mPFS; estimated by Kaplan-Meier methods]). ctDNA sequencing was conducted retrospectively with AmoyDx (Chinese pts) and Resolution Bio ctDx™ next-generation sequencing panels. Tumor size was represented as sum of the longest diameter (SLD) of target lesions (RECIST v1.1 criteria). Association between ALK status and clinical features was estimated by odds ratios (OR).
Results
Of 248 pts in ALTA-3, ctDNA from plasma collected at BL from 232 pts was sequenced. ALK fusions were detected in 78 (ALK ctDNA+) and not detected in 154 (ALK ctDNA−). ALK ctDNA− pts had longer mPFS compared with ALK ctDNA+ pts (mPFS 22.5 vs 11.1 months, respectively; hazard ratio 0.48; 95% confidence interval [CI] 0.32–0.71; P=0.0002). ALK ctDNA− pts were more likely to have SLD less than or equal to the median (39 mm) compared with ALK ctDNA+ pts (OR 0.32, 95% CI 0.17–0.59). ALK ctDNA+ status was associated with >1 (median) BL target lesion (OR 0.27, 95% CI 0.14–0.50) and >3 (median) involved organ sites (OR 0.40, 95% CI 0.21–0.73). Smoking status did not impact ctDNA detection of ALK fusion status or outcomes.
Conclusions
Detectable BL ALK fusion by plasma ctDNA is an indicator of poor prognosis and is associated with increased tumor size, number of metastases, and organ site involvement. ALK fusion detection using BL ctDNA could be a surrogate for disease burden and may identify pt populations for escalation strategies in the future.
Clinical trial identification
NCT03596866.
Editorial acknowledgement
Medical writing and editorial support was provided by Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA.
Legal entity responsible for the study
Takeda Development Center Americas, Inc.
Funding
Takeda Development Center Americas, Inc.
Disclosure
C. Aggarwal: Financial Interests, Institutional, Research Funding: AstraZeneca, Genentech, Incyte, Macrogenics, Medimmune, and Merck Sharp & Dohme; Financial Interests, Personal, Other, Consultation fees: Genentech, Lilly, Celgene Merck, AstraZeneca, Blueprint Genetics, Shionogi, Daiichi Sankyo/ AstraZeneca, Regeneron/ Sanofi, Eisai, BeiGene, Turning Point, Pfizer, Janssen, Boehringer Ingelheim. A. Barakat, X. Tong, A. Krueger, B. Hupf, R. Fram, S. Vincent: Financial Interests, Personal, Full or part-time Employment: Takeda.
Resources from the same session
1057P - Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
Presenter: Jian Li
Session: Poster session 19
1058P - Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer
Presenter: Hsiu-Tzu Wang
Session: Poster session 19
1059P - Tertiary lymphoid structures localization and maturation heterogeneities correlate with divergent clinical outcomes and immune responses of clear cell renal cell carcinoma
Presenter: Dingwei Ye
Session: Poster session 19
1061P - Association of transcriptomic mapping of tumors with high expression of Tregs to identify surfaceome gene signatures with efficacy to check point inhibitors
Presenter: María Del Mar Noblejas Lopez
Session: Poster session 19
1062P - Anti-PD1 efficacy in European patients with advanced MSI-H/MMRd non-colorectal cancers
Presenter: Christophe Tournigand
Session: Poster session 19
1063P - Differential tumor responses are a poor prognostic factor in patients receiving immune checkpoint inhibitors
Presenter: Caterina Tozzi
Session: Poster session 19
1065P - Prospective assessment of nutritional status in patients with advanced non-small cell lung cancer and renal cell carcinoma treated with immune checkpoint inhibitors
Presenter: Federica Pecci
Session: Poster session 19
1066P - Negative impact of steroids on the efficacy of immunotherapy in a multi-tumor cohort of patients: time and dose-dependent
Presenter: Víctor Albarrán
Session: Poster session 19
1067P - The interchangeability of Immune checkpoint inhibitors
Presenter: Lonneke Timmers
Session: Poster session 19